Janus Kinase 2

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.

Ruxolitinib induced responses in about one-third of a cohort of patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, according to results of a single-arm phase 2 study published in Journal of Clinical Oncology.